Clinical pharmacology of chemotherapy agents in older people with cancer
- PMID: 21845189
- PMCID: PMC3154497
- DOI: 10.1155/2011/628670
Clinical pharmacology of chemotherapy agents in older people with cancer
Abstract
Populations around the world are aging, and the associated increase in cancer incidence has led to the recognition of the importance of geriatric oncology. Chronological age is a poor determinant of pharmacological response to cancer chemotherapy agents. Age-associated changes in physiology and organ function have a significant impact on the clinical pharmacology of cancer chemotherapy agents used in cancer treatment. Altered response to medicines in older people is a consequence of changes in body composition, organ function, concomitant pathophysiology, multiple medications, genetic determinants of drug response, and patient's clinical status. These issues highlight the need to individualize the management of cancer in the older people with consideration of age-related changes in the clinical pharmacology of cancer drugs, analgesics, and adjunctive therapies.
Similar articles
-
Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol.BMC Cancer. 2019 Nov 27;19(1):1153. doi: 10.1186/s12885-019-6377-7. BMC Cancer. 2019. PMID: 31775667 Free PMC article.
-
Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.Br J Clin Pharmacol. 2011 Mar;71(3):351-64. doi: 10.1111/j.1365-2125.2010.03847.x. Br J Clin Pharmacol. 2011. PMID: 21284694 Free PMC article. Review.
-
Pharmacokinetics of chemotherapy in the older patient.Cancer Control. 2007 Jan;14(1):32-43. doi: 10.1177/107327480701400105. Cancer Control. 2007. PMID: 17242669 Review.
-
Chemotherapy in the geriatric population.Clin J Oncol Nurs. 2004 Dec;8(6):591-7. doi: 10.1188/04.CJON.591-597. Clin J Oncol Nurs. 2004. PMID: 15637954 Review.
-
Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review.Eur Urol Focus. 2017 Oct;3(4-5):330-339. doi: 10.1016/j.euf.2017.10.010. Epub 2018 Jan 10. Eur Urol Focus. 2017. PMID: 29331624 Review.
Cited by
-
Potential drug interactions in patients with a history of cancer.Curr Oncol. 2014 Apr;21(2):e212-20. doi: 10.3747/co.21.1657. Curr Oncol. 2014. PMID: 24764706 Free PMC article.
-
Polypharmacy in older adults: the role of the advanced practitioner in oncology.J Adv Pract Oncol. 2013 Mar;4(2):107-12. J Adv Pract Oncol. 2013. PMID: 25031989 Free PMC article. Review. No abstract available.
-
Do we protect or discriminate? Representation of senior adults in clinical trials.Rep Pract Oncol Radiother. 2012 Sep 26;18(1):6-10. doi: 10.1016/j.rpor.2012.08.006. eCollection 2012. Rep Pract Oncol Radiother. 2012. PMID: 24381741 Free PMC article.
-
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.Clin Transl Sci. 2018 Mar;11(2):123-146. doi: 10.1111/cts.12527. Epub 2017 Dec 19. Clin Transl Sci. 2018. PMID: 29266809 Free PMC article. Review. No abstract available.
References
-
- Balducci L, Extermann M. Cancer and aging: an evolving panorama. Hematology/Oncology Clinics of North America. 2000;14(1):1–16. - PubMed
-
- Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control. 2007;14(1):32–43. - PubMed
-
- McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacological Reviews. 2004;56(2):163–184. - PubMed
-
- Lichtman SM. Guidelines for the treatment of elderly cancer patients. Cancer Control. 2003;10(6):445–453. - PubMed
-
- Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer Journal. 2005;11(6):449–460. - PubMed
LinkOut - more resources
Full Text Sources
